HNCDrugResDb

HNCDrugResDb

Head and Neck Cancer Drug Resistance Database

HNCDrugResDb


HNCDrugResDb is a freely accessible database of molecular expression level alterations in proteins, multiple post-translational modifications, mRNAs, long non-coding RNAs and microRNAs associated with drug resistance in Head and Neck Cancers (HNC). Currently, the database encompasses differential regulation events of over 661 proteins, 166 PTMs, 1121 mRNAs, 203 microRNAs and 49 lncRNAs in response to 14 anti-cancer drugs in 58 different HNC cell lines. HNCDrugResDb is user-friendly to browse information through the selection of drug name, cancer type or molecule type that directs to further details in the context of experimental methods, cell lines, expression pattern and also to their potential biomarker type. All the information is linked to their corresponding research article for further reference. A “Drug Resistance Analysis” module is enabled in HNCDrugResDb for researchers/clinicians to query RNA/proteins quantified/differentially regulated in their subjective HNC tissue/cell line samples to predict the likelihood of drug resistance. The Query Search interface allow the users to input proteins/mRNAs/miRNAs/lncRNAs of interest to retrieve their enrichment in HNCDrugResDb dataset. In addition, HNCDrugResDb also hosts the extensively annotated signaling events associated with HNC drug resistance to various drugs.

HNCDrugResDb serves as a repository of meticulously curated information concerning differentially expressed RNAs, proteins, miRNAs, and lncRNAs sourced from publicly available research articles associated with drug resistance in head and neck cancer. Head and neck cancer ranks as the seventh most prevalent form of cancer on a global scale, manifesting in diverse regions of the upper aerodigestive tract. Despite the existence of efficacious treatment modalities, a substantial portion of patients eventually acquires resistance to these treatments following an initial positive response, thereby posing a significant impediment to the success of cancer therapy. Cancer cells employ a variety of mechanisms to surmount the cytotoxic effects of drugs, encompassing alterations in gene and protein expression, as well as the activation of alternative signaling pathways. Recent research has illuminated the pivotal roles of miRNAs and lncRNAs in mediating drug resistance by targeting genes implicated in this phenomenon. To effectively combat drug resistance, it is imperative to gain a comprehensive understanding of the underlying molecular modifications and pathways implicated in this resistance. Consequently, we have compiled an extensive dataset that encompasses all altered molecules associated with drug resistance in HNC upon treatment with frontline anti-cancer drugs, encompassing both driver and differentially expressed molecules implicated in this resistance.


Tools